Systemic oxidative stress, as measured by urinary allantoin and F2-isoprostanes, is not increased in down syndrome

Annals of Epidemiology

Volumn 22, Issue 12, 2012, Pages 892-894

  Tolun, Adviye A ^a,b   Scarbrough, Peter M ^a   Zhang, Haoyue ^a   McKillop, Jane Ann ^a   Wang, Frances ^a   Kishnani, Priya S ^a   Millington, David S ^a   Young, Sarah P ^a   Il'yasova, Dora ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b LABORATORY CORPORATION OF AMERICA   (United States)

Author keywords

Biomarker; Down syndrome; Tandem mass spectrometry; Urine

Indexed keywords

ALLANTOIN; CREATININE; ISOPROSTANE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHEMICAL ANALYSIS; CHILD; CLINICAL ARTICLE; CREATININE URINE LEVEL; DISEASE MARKER; DOWN SYNDROME; FEMALE; HUMAN; MALE; OXIDATIVE STRESS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; URINALYSIS;

ADOLESCENT; ADULT; AGED; ALLANTOIN; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, LIQUID; DOWN SYNDROME; F2-ISOPROSTANES; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84870251623     PISSN: 10472797     EISSN: 18732585     Source Type: Journal    
DOI: 10.1016/j.annepidem.2012.09.005     Document Type: Article

References (25)

1. Roizen N.J., Patterson D. Down's syndrome. Lancet 2003, 361:1281-1289.
2. Zitnanova I., Korytar P., Sobotova H., et al. Markers of oxidative stress in children with Down syndrome. Clin Chem Lab Med 2006, 44:306-310.
3. de Haan J.B., Wolvetang E.J., Cristiano F., et al. Reactive oxygen species and their contribution to pathology in Down syndrome. Adv Pharmacol 1997, 38:379-402.
4. Busciglio J., Yankner B.A. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 1995, 378:776-779.
5. Salman M. Systematic review of the effect of therapeutic dietary supplements and drugs on cognitive function in subjects with Down syndrome. Eur J Paediatr Neurol 2002, 6:213-219.
6. Roizen N.J. Complementary and alternative therapies for Down syndrome. Ment Retard Dev Disabil Res Rev 2005, 11:149-155.
7. Heller J.H., Spiridigliozzi G.A., Crissman B.G., Sullivan-Saarela J.A., Li J.S., Kishnani P.S. Clinical trials in children with Down syndrome: issues from a cognitive research perspective. Am J Med Genet C Semin Med Genet 2006, 142C:187-195.
8. Il'yasova D., Spasojevic I., Wang F., et al. Urinary biomarkers of oxidative status in a clinical model of oxidative assault. Cancer Epidemiol Biomarkers Prev 2010, 19:1506-1510.
9. Kadiiska M.B., Gladen B.C., Baird D.D., et al. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning?. Free Radic Biol Med 2005, 38:698-710.
10. Zhang H., Il'yasova D., Sztaray J., Young S.P., Wang F., Millington D.S. Quantification of the oxidative damage biomarker 2,3-dinor-8-isoprostaglandin-F(2alpha) in human urine using liquid chromatography-tandem mass spectrometry. Anal Biochem 2010, 399:302-304.
11. Tolun A.A., Zhang H., Il'yasova D., Sztaray J., Young S.P., Millington D.S. Allantoin in human urine quantified by ultra-performance liquid chromatography-tandem mass spectrometry. Anal Biochem 2010, 402:191-193.
12. An Y., Young S.P., Kishnani P.S., et al. Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease. Mol Genet Metab 2005, 85:247-254.
13. Young S.P., Zhang H., Corzo D., et al. Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker. Genet Med 2009, 11:536-541.
14. Zitnanova I., Korytar P., Aruoma O.I., et al. Uric acid and allantoin levels in Down syndrome: antioxidant and oxidative stress mechanisms?. Clin Chim Acta 2004, 341:139-146.
15. Pratico D., Iuliano L., Amerio G., et al. Down's syndrome is associated with increased 8,12-iso-iPF2alpha-VI levels: evidence for enhanced lipid peroxidation in vivo. Ann Neurol 2000, 48:795-798.
16. Campos C., Guzman R., Lopez-Fernandez E., Casado A. Evaluation of urinary biomarkers of oxidative/nitrosative stress in adolescents and adults with Down syndrome. Biochim Biophys Acta 2011, 1812:760-768.
17. Campos C., Guzman R., Lopez-Fernandez E., Casado A. Evaluation of urinary biomarkers of oxidative/nitrosative stress in children with Down syndrome. Life Sci 2011, 89:655-661.
18. Zana M., Janka Z., Kalman J. Oxidative stress: a bridge between Down's syndrome and Alzheimer's disease. Neurobiol Aging 2007, 28:648-676.
19. Strydom A., Dickinson M.J., Shende S., Pratico D., Walker Z. Oxidative stress and cognitive ability in adults with Down syndrome. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:76-80.
20. Pallardo F.V., Degan P., d'Ischia M., et al. Multiple evidence for an early age pro-oxidant state in Down Syndrome patients. Biogerontology 2006, 7:211-220.
21. Zana M., Szecsenyi A., Czibula A., et al. Age-dependent oxidative stress-induced DNA damage in Down's lymphocytes. Biochem Biophys Res Commun 2006, 345:726-733.
22. Kauffman L.D., Sokol R.J., Jones R.H., Awad J.A., Rewers M.J., Norris J.M. Urinary F2-isoprostanes in young healthy children at risk for type 1 diabetes mellitus. Free Radic Biol Med 2003, 35:551-557.
23. Tamura S., Tsukahara H., Ueno M., et al. Evaluation of a urinary multi-parameter biomarker set for oxidative stress in children, adolescents and young adults. Free Radic Res 2006, 40:1198-1205.
24. Il'yasova D., Wang F., Spasojevic I., Base K., D'Agostino R.B., Wagenknecht L.E. Urinary F(2)-isoprostanes, obesity, and weight gain in the IRAS cohort. Obesity (Silver Spring) 2012, 20:1915-1921.
25. Ani C., Grantham-McGregor S., Muller D. Nutritional supplementation in Down syndrome: theoretical considerations and current status. Dev Med Child Neurol 2000, 42:207-213.